Faeth to Present Preclinical Data on PIKTOR in HR+/HER2- Breast Cancer Models at ESMO 2026
Faeth Therapeutics will present preclinical data on PIKTOR in HR+/HER2- breast cancer models at the ESMO Congress 2026, with the poster scheduled for October 23 in Madrid. The poster characterizes PIKTOR as monotherapy and in combination with fulvestrant, oral SERDs, and CDK inhibitors, and includes head-to-head xenograft comparisons with gedatolisib, another multi-nodal PI3K-AKT-mTOR pathway inhibitor.
Key figures
- Drug Name
- PIKTOR (serabelisib + sapanisertib)
- Phase Of Trial
- Phase 1b/2
- Abstract number
- 431P
- Pam pathway dysregulation
- up to 50% of all solid tumors
AI analysis
Red flags2 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.